MedTrace Logo

To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects

NCT04525079 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-11-16

Study results available
· View outcomes & findings →

Summary

This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects.

Conditions

Interventions

DRUG

CT-P59

CT-P59 will be administered

DRUG

Placebo

Placebo-matching CT-P59

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-18
Primary Completion
2020-08-07
Completion
2020-11-05
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04525079 on ClinicalTrials.gov